Page last updated: 2024-12-08
aklavinone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
aklavinone: from Streptomyces galilaeus MA 144-M1, strain 3AR-33; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 159776 |
CHEBI ID | 31181 |
SCHEMBL ID | 116665 |
MeSH ID | M0090133 |
Synonyms (23)
Synonym |
---|
nsc 114780 |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7-tetrahydroxy-6,11-dioxo-, methyl ester, [1r-(1alpha,2beta,4beta)]- |
aklavinone (6ci,7ci) |
ccris 7635 |
aklavinon |
nsc-114780 |
aklavinone |
aclavinone |
antibiotic ma 144d1 |
16234-96-1 |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7-tetrahydroxy-6,11-dioxo-, methyl ester, (1r,2r,4s)- |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7-tetrahydroxy-6,11-dioxo-, methyl ester, (1r,2r,4s)- (8ci,9ci) |
methyl (1r,2r,4s)-2-ethyl-2,4,5,7-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate |
CHEBI:31181 |
methyl 2-ethyl-2,4,5,7-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate |
methyl (1r,2r,4s)-2-ethyl-2,4,5,7-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate |
unii-j8nh9fr49n |
j8nh9fr49n , |
SCHEMBL116665 |
Q27114195 |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7-tetrahydroxy-6,11-dioxo-, methyl ester, (1r,2r,4s)- (8ci) |
methyl (1r,2r,4s)-2-ethyl-1,2,3,4,6,11-hexahydro-2,4,5,7-tetrahydroxy-6,11-dioxo-1-naphthacenecarboxylate |
AKOS040750267 |
Research Excerpts
Overview
Aklavinone is an aglycone of aclacinomycin A which is an important antitumor drug.
Excerpt | Reference | Relevance |
---|---|---|
"Aklavinone is an aglycone of aclacinomycin A which is an important antitumor drug. " | ( Cloning of aklavinone biosynthesis genes from Streptomyces galilaeus. Ebizuka, Y; Fujii, I; Sankawa, U; Tsukamoto, N, 1992) | 2.12 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
Role | Description |
---|---|
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
---|---|
anthracycline | Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine. |
tetracenequinones | |
methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathways (2)
Pathway | Proteins | Compounds |
---|---|---|
daunorubicin biosynthesis | 19 | 30 |
aclacinomycin biosynthesis | 14 | 28 |
Research
Studies (24)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (33.33) | 18.7374 |
1990's | 8 (33.33) | 18.2507 |
2000's | 6 (25.00) | 29.6817 |
2010's | 2 (8.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 24 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |